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Abstract 
 
Background: Based on beneficial reports of pamidronate use for reflex sympathetic dystrophy in reduction of 
pain and swelling, this drug can be studied as a novel treatment for refractory lymphedema. This study aims to 
determine the effectiveness of pamidronate on lymphedema and its possible side effects.  
 
Methods: Twelve cases of lower limb refractory lymphedema were enrolled. They received intravenous pami-
dronate monthly for 3 consecutive months and were followed by measuring any discomfort with visual analog 
scale (VAS) and physician global assessment, based on objective signs of limb volume and circumference.  
 
Results: The limb volume, circumference, and satisfaction of the patients improved significantly.  
 
Conclusion: Pamidronate when is added to conservative treatments may reduce lymphedema and improve the 
patient’s comfort. 
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Introduction 
 
Lymphedema  is  generally  defined  as  an  excessive 
regional  accumulation  of  protein-  rich  fluid  in  the 
extravascular interstitial spaces as a consequence of 
impaired lymphatic drainage,
1-3 and is a frequent but 
often  neglected  sequel  of  cancer  treatment.
4-7  The 
lymphedema in extremities may cause great discom-
fort  for  the  patient  due  to  accumulation  of  large 
amounts of fluid causing restriction in joint motion.
4-6 
The standard treatment for this edema has been the 
use  of  bandaging  (stocking,  sleeves),  compression 
garment,  exercise,  manual  lymphatic  drainage,  and 
skin care.
1,3,8-10   Nevertheless, some of patients with 
persistent or reluctant extremity lymphedema need an 
additional treatment measure.
10-18 The most common-
ly used drugs in lymphedema are benzopyrones,
19,20 
but a rate of 6% hepatotoxicity reported in an Ameri-
can  multicenter  study  caused  benzopyrone  prepara-
tions not to be recommended for a long term thera-
py.
21  Other  described  drugs  such  as  corticosteroids 
and diuretics are also not recommended for the treat-
ment of lymphedema.
1,8,21 Effects of pamidronate on 
bone physiology and in reflex sympathetic dystrophy 
have  been  previously  investigated.  It  has  an  osteo-
clastic inhibitory effect and has the ability to inhibit 
afferent nerve fibers,
22-25 but little is known about the 
basic pharmacologic mechanisms of pamidronate and 
its effects on reduction of edema.
 After recent benefi-
cial effects using pamidronate in treatment of reflex 
sympathetic dystrophy with a low rate of side effects, 
pamidronate can be a novel option for therapy of recal-
citrant  lymphedema  that  is  not  investigated  before. 
This study investigates the efficacy and possible side 
effects of pamidronate on lymphedema. 
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Materials and Methods 
 
Between January and June 2007, 12 consecutive pa-
tients with at least 6 months persistent or progressive 
lymphedema, unresponsive to traditional treatments, 
underwent  treatment  with  intravenous  pamidronate, 
after providing a written consent from each patient. 
Lymphedema diagnosis was based on history, physi-
cal  examination  and  was  confirmed  with  radio-
isotope  lymphangiography.  Computed  tomography 
and Doppler sonography were performed if there was 
any doubt about the diagnosis.  
The patients were excluded if they had a metastat-
ic  disease,  developing  severe  side  effects  or  devel-
oped lymphedema after a surgical procedure.  All pa-
tients  had  moderate  to  severe  lymphedema  without 
any  elephantiasis  (Miller’s  stage  П)  3  and  with  no 
renal insufficiency. It means that the edema was not 
spontaneously reversible by elevation or compression 
of the limb and a moderate to severe fibrosis was pre-
sent.  These  patients  had  recalcitrant  chronic 
lymphedema  without  any  response  to  conservative 
management  such  as  physiotherapy  (manual  drain-
age)  or  compression  by  pump,  elastic  sleeves  and 
stockings.  
All  patients  received  calcium  supplement  before 
beginning of infusion if they had a normal or low cal-
cium serum level. Disodium pamidronate concentrat-
ed solution (15 mg/ml; Wockhardt; UK) was adminis-
tered intravenously once a month for 3 consecutive 
months (60 mg was diluted in 500 ml of dextrose or 
saline and infused during six hours). None of them 
had  received  other  additional  medications,  such  as 
steroids  or  benzopyrones  for  reduction  of  extremity 
edema.  After  receiving  pamidronate,  they  continued 
their conservative treatment by elevation and compres-
sion stockings. Follow up examinations of patients was 
performed once a month during the treatment course 
and 3 months after by the same physician.  
They were asked about side effects of drug (such 
as headache, myalgia and fever) and the relief of re-
lated  previous  complaints  (such  as  limb  heaviness, 
pressure sensation and limitation of movement). Ob-
jective  evaluation  by  physician  was  also  included 
measuring  the  discomfort  by  visual  analog  scale 
(VAS) and measuring of patient’s limb volume, and 
limb  circumference.  Patient’s  limb  volume  was 
measured  at  each  examination  by  water  volumetry 
with using a measured tank and their lower limb cir-
cumference was measured at eight points with 10 cm 
intervals from the medial maleous to upper thigh. The 
Quantitative  data  from  repeated  measurements  of 
limb volume and circumference were analyzed using 
SPSS software (Version 15, Chicago, IL, USA).  
 
 
Results 
 
Among  12  patients,  five  were  men  and  seven  were 
women with an average age of 38.4 years (range: 24-61 
years) received 3 consecutive courses of pamidronate. 
Table 1 summarizes the patient characteristics including 
age, sex, site, duration and etiology of the disease. Be-
fore treatment, all patients complained from lower limb 
edema  (lymphedema)  affecting  their  normal  life  and 
activity but after treatment with pamidronate, most of 
them felt much well and they could do their daily activi-
ties much better. Table 2 shows the baseline and subse-
quent measurements that were carried out for patients 
demonstrating a pretreatment median VAS score of 80 
and a statistically significant change after the first infu-
sion and a decrease to 16 after 3 months treatment with 
pamidronate  (p=0.001)  (Figure  1).  The  limb  volume 
progressively  decreased  in  affected  limb  with  each 
Table 1: Characteristics of 12 lymphedema patients treated with pamidronate 
Patient  Sex  Age  Site  Aetiology  Disease dura-
tion (Months) 
1  F  38  LLE
a  Idiopathic  18 
2  M  45  RLE
b  Idiopathic  12 
3  F  61  LLE  Idiopathic  10 
4  F  49  LUE
c  Idiopathic  8 
5  F  38  LLE  Idiopathic  12 
6  M  36  LLE  Secondry  10 
7  M  45  LLE  Idiopathic  15 
8  F  39  LLE  Idiopathic  11 
9  M  24  LLE  Idiopathic  9 
10  F  29  LLE  Idiopathic  14 
11  F  36  LLE  Idiopathic  16 
12  M  47  LLE  Idiopathic  7 
a LLE, Left Lower Extremity; 
b RLE, Right Lower Extremity; 
c LUE, Left Upper Extremity 
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infusion of the drug and the mean lower limb circum-
ference reduced in all measured points following each 
infusion of pamidronate. Except short time myalgia, 
no other serious side effect was noticed during or af-
ter administration of pamidronate. The data showed a 
considerable  improvement  of  the  lymphedema  fol-
lowing treatment with pamidronate, specially the sub-
jective satisfaction of the patients and the functional 
improvement of them.  
 
 
Discussion  
 
Extremity  lymphedema  may  cause  great discomfort 
for  the  patient  and  most  of  the  cases  inadequately  
responded  to  the  treatment,  thus  efforts  to  increase 
patients’ comfort are greatly needed. This case se-
ries  are  the  first  report  of  pamidronate  use  for 
lymphedema  which  was added  to  management of 
the  patients  due  to  inadequate  response  to  con-
servative managements such as limb elevation and 
compression  therapy.  The  results  showed  that 
pamidronate had incredible effects on lymphedema, 
with  improved  patient’s  comfort,  increased  func-
tional capacity, and reduced their limb volume. We 
did not find any predictive factor for response to 
pamidronate.  It  is  well  tolerated  without  any  life 
threatening  side effect in  these  patients.  Some  of 
possible speculations on the mechanism of action 
of pamidronate in lymphedema could be a reduc-
tion of vasodilation, an inhibitory effect on the af-
ferent nerves and the neuropeptide release.
24 These 
effects  could  explain  both  pain  and  reduction  in 
Table 2: Changes of limb volume, circumferences and discomfort (VAS) after pamidronate infusions 
  Mean volume
a (Liter)  Mean circumferences
a (cm)  VAS
b (0-100 mm) 
Baseline  4.56±0.8  39.5±9.7  80±12 
1 
st infusion  4.48±0.9  38.8±4.9  48±16 
2 
nd infusion  4.37±1.1  36.5±4.5  24±13 
3 
rd infusion  4.12±1.2  35.3±3.1  16± 5 
Differences  -0.44  -4.2  -64 
a Measurements one month after infusion, 
bPain and discomfort one month after infusion. 
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Fig. 1: Mean Visual Analogue Score after each infusion of sodium Pamidronate  
(VAS:Visual Analogue Score ,each one months apart) 
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limb edema with interaction with the microcircula-
tion, tissue trophism, etc. 
The absence of a control group was the limitation of 
our study but it provides an objective evidence for the 
effectiveness of pamidronate to be well tolerated with-
out any life threatening side effect. However, the need 
for an intravenous use and reduction of cost are a matter 
of concern.  Our study may provide a new therapeutic 
option  to  improve  the  quality  of  life  of  patients 
suffering from refractory lymphedema. However, fur-
ther randomized, double blind, controlled placebo in-
vestigations are necessary to confirm these benefits. 
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